Outpatient management in patients with neutropenia after intensive chemotherpay - Is it safe?

Annals of Oncology

Volumn 16, Issue 2, 2005, Pages 179-180

  Kern, W V ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; FLUCONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACUTE LEUKEMIA; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BACTEREMIA; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COST CONTROL; DISEASE DURATION; DRUG FEVER; EDITORIAL; FEBRILE NEUTROPENIA; HEALTH CARE COST; HIGH RISK PATIENT; HOME CARE; HOSPITAL ADMISSION; HOSPITAL CARE; HOSPITAL DISCHARGE; HUMAN; INFECTION; INFECTION RATE; LENGTH OF STAY; LEUKEMIA REMISSION; LYMPHOMA; NEUTROPENIA; OUTPATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; SAFETY; SEPTICEMIA;

ACUTE DISEASE; ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BACTEREMIA; HUMANS; LEUKEMIA; NEUTROPENIA; OUTPATIENTS; PROGNOSIS;

EID: 14644403044     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi067     Document Type: Editorial

References (10)

1. Gilbert C, Meisenberg B, Vredenburgh J et al. Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 1994; 12: 1005-1011.
2. Kern WV. Risk assessment and risk-based therapeutic strategies in febrile neutropenia. Curr Opin Infect Dis 2000; 14: 415-422.
3. Rovira M. Outpatient management of autologous haematopoietic cell transplantation: the Barcelona experience. Presse Med 2004; 33: 479-481.
4. Morabito F, Martino M, Stelitano C et al. Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. Haematologica 2002; 87: 1192-1199.
5. Summers N, Dawe U, Stewart DA. A comparison of inpatient and outpatient ASCT. Bone Marrow Transplant 2000; 26: 389-395.
6. Meisenberg BR, Miller WE, McMillan R et al. Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies. J Clin Oncol 1997: 15: 11-17.
7. Westermann AM, Holtkamp MM, Linthorst GA et al. At home management of aplastic phase following high-dose chemotherapy with stem-cell resue for hematological and non-hematological malignancies. Ann Oncol 1999; 10: 511-517.
8. Russell JA, Chaudhry A, Booth K et al. Early outcomes after allogeneic stem cell transplantation for leukaemia and myelodysplasia without protective isolation: a 10-year experience. Biol Blood Marrow Transplant 2000; 6: 109-114.
9. Meisenberg BR, Ferran K, Hollenbach K et al. Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant 1998; 21: 927-932.
10. van Tiel FH, Harbers MM, Kessels AG, Schouten HC. Home care versus hospital care of patients with hematological malignancies and chemotherapy-induced cytopenia. Ann Oncol 2005; 16: 195-205.